Last updated: April 1, 2025
Sponsor: Research Institute of Epidemiology, Microbiology and Infectious Diseases, Uzbekistan
Overall Status: Active - Not Recruiting
Phase
2/3
Condition
Gastroenteritis
Infectious Colitis
Treatment
20-hydroxyecdysone Oral
Placebo Oral
Metronidazole Oral
Clinical Study ID
NCT04827537
2019121819
Ages 18-27 Male
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- a presence of giardia lamblia in stool samples of partisipants
Exclusion
Exclusion Criteria:
chronic and acute infectious diseases,
endocrine diseases, congenital diseases,
allergic dermatitis,
bronchial asthma,
allergic rhinitis and/or conjunctivitis,
other skin disorders,
history of using vitamin D supplements within three months ago, or use of anymedication influencing endocrine parameters.
Study Design
Total Participants: 200
Treatment Group(s): 3
Primary Treatment: 20-hydroxyecdysone Oral
Phase: 2/3
Study Start date:
January 01, 2021
Estimated Completion Date:
December 31, 2027
Study Description
Connect with a study center
Research institute of epidemiology, microbiology and infectious diseases
Tashkent, Uchtepa 100133
UzbekistanSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.